Kalium Chloratum Léčiva (Potassium Chloride)

After injection, potassium chloride dissociates into potassium ions, which raise extracellular potassium levels. This restores the normal potassium gradient across cell membranes, stabilizing cardiac and muscular electrical activity and supporting overall cellular function.

The dose of Kalium Chloratum Léčiva is individualized by the prescribing clinician based on the patient’s serum potassium level, renal function, and clinical condition. Healthcare providers calculate the appropriate volume and rate of infusion for each case.

The safety of Kalium Chloratum Léčiva in pregnancy and lactation has not been definitively established. It should only be used if the potential benefit justifies any potential risk to the fetus or infant, and under close medical supervision.

To order, submit an enquiry on the product page at gnhindia.com specifying the required quantity. GNH India works with hospitals, pharmacies, and procurement teams worldwide, verifies trade or institutional credentials, and then provides pricing, availability, shipping details (including cold‑chain where needed), and import documentation.

Kalium Chloratum Léčiva is an injectable formulation, offering rapid correction of potassium deficits compared with oral potassium salts, which act more slowly and may cause gastrointestinal irritation. It is preferred in acute care settings where immediate electrolyte restoration is critical.

The solution should be stored at 2‑8 °C, protected from light, and must not be frozen or shaken. Keep the product in its original packaging until use to maintain sterility and potency.

Kalium Chloratum Léčiva is administered intravenously by a qualified healthcare professional. The infusion rate is determined by the prescriber, taking into account the patient’s potassium level, cardiac status, and renal function to avoid rapid shifts in serum potassium.

The most serious risks include severe hyperkalemia, which can cause life‑threatening cardiac arrhythmias or cardiac arrest, as well as anaphylactic reactions and severe hypotension. Continuous monitoring of cardiac rhythm and serum potassium is essential during administration.

Patients with known hypersensitivity to potassium chloride, severe renal impairment, uncontrolled hyperkalemia, or those taking multiple potassium‑raising agents without close monitoring should not receive Kalium Chloratum Léčiva unless under strict medical supervision.